How many drugs treat Amyloidosis?

Drug Landscape tracks 8 marketed treatments for Amyloidosis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/amyloidosis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Amyloidosis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Amyloidosis (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Amyloidosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Vyndaqel	Tafamidis	Foldrx Pharms	tafamidis	Transthyretin	2019-01-01
Vyndaqel	Tafamidis Meglumine	Foldrx Pharms	Transthyretin stabilizer	Transthyretin (TTR)	2019-01-01
Vyndaqel	tafamidis-test	Foldrx Pharms	tafamidis	Transthyretin	2019-01-01
Cysteine Hydrochloride	CYSTEINE	Exela Pharma	Vitamin C [EPC]	Cystine/glutamate transporter	1986-01-01
Acetadote	Acetylcysteine	Bristol-Myers Squibb	Antidote	Glutathione levels; reactive metabolite of acetaminophen	1963-01-01
Acetylcystein	Acetylcystein	University Hospital, Strasbourg, France		Cystine/glutamate transporter, Cytochrome c, Glutathione synthetase
L-cysteine	L-cysteine	Louisiana State University Health Sciences Center Shreveport	Amino acid derivative	Cystine/glutamate transporter
Acetadote	Acetadote	University of Texas Southwestern Medical Center		Cystine/glutamate transporter, Cytochrome c, Glutathione synthetase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Foldrx Pharms · 4 drugs in Amyloidosis
Bristol-Myers Squibb · 1 drug in Amyloidosis
Exela Pharma · 1 drug in Amyloidosis
Louisiana State University Health Sciences Center Shreveport · 1 drug in Amyloidosis
University Hospital, Strasbourg, France · 1 drug in Amyloidosis
University of Texas Southwestern Medical Center · 1 drug in Amyloidosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Amyloidosis:

Cite this brief

Drug Landscape (2026). Amyloidosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/amyloidosis. Accessed 2026-06-10.

Amyloidosis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing